Stockscreener 앱 받기
1.05
6.06%
0.06
시간 외 거래:
1.03
-0.02
-1.90%
전일 마감가:
$0.99
열려 있는:
$1.02
하루 거래량:
2.20M
Relative Volume:
3.00
시가총액:
$24.63M
수익:
$7.10M
순이익/손실:
$-31.59M
주가수익비율:
-0.4023
EPS:
-2.61
순현금흐름:
$-26.75M
1주 성능:
+15.19%
1개월 성능:
-13.22%
6개월 성능:
-23.36%
1년 성능:
-74.33%
1일 변동 폭
$1.01
$1.15
1주일 범위
$0.79
$1.38
52주 변동 폭
$0.68
$4.65
Palatin Technologies Inc. Stock (PTN) Company Profile
명칭
Palatin Technologies Inc.
전화
609-495-2200
주소
Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ
PTN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTN
Palatin Technologies Inc.
|
1.05 | 24.63M | 7.10M | -31.59M | -26.75M | -2.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 120.86B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 77.62B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.62B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2015-06-05 | 재확인 | Canaccord Genuity | Buy |
| 2015-01-12 | 재확인 | ROTH Capital | Buy |
| 2012-05-23 | 개시 | Noble Financial | Buy |
| 2007-01-23 | 개시 | Next Generation | Buy |
Palatin Technologies Inc. 주식(PTN)의 최신 뉴스
Palatin Technologies Inc [PTN] stock for 8,274 USD was sold by WILLS STEPHEN T - Knox Daily
Palatin Technologies prices 4.69M shares in direct offering - MSN
Palatin Gains on New Offering - Baystreet.ca
Palatin Technologies Announces $4.7 Mln Direct Offering - Nasdaq
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement - Marketscreener.com
Palatin secures $4.7 million in stock and warrant sale - Investing.com
Palatin secures $4.7 million in stock and warrant sale By Investing.com - Investing.com UK
Palatin's Strategic $4.7M Healthcare Investment Deal: Inside the Critical Financing Terms - StockTitan
Palatin concludes Phase II trial of combination therapy for obesity - Clinical Trials Arena
As Saudi Arabia’s Tourism Sector Grows Exponentially, dmg events Announces Hotel & Hospitality Expo - GlobeNewswire Inc.
Palatin finishes phase 2 trial in obesity treatment study By Investing.com - Investing.com Nigeria
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide - GuruFocus.com
Palatin finishes phase 2 trial in obesity treatment study - Investing.com
Obesity Treatment Breakthrough? Palatin's Novel GLP-1 Combo Trial Wraps Up With Massive Patient Interest - StockTitan
PTN’s price-to-sales ratio: A comparative analysis with its peers - US Post News
Palatin Technologies Inc (PTN) Stock: What the Analysts are Saying - The News Heater
PTN’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Market Watch: Palatin Technologies Inc (PTN)’s Noteworthy Drop, Closing at 0.80 - The Dwinnex
Palatin Technologies (NYSEAMERICAN:PTN) Earns “Buy” Rating from HC Wainwright - Defense World
Palatin gears up for obesity treatment trials in 2025 By Investing.com - Investing.com Canada
Palatin gears up for obesity treatment trials in 2025 - MSN
Palatin's Game-Changing Obesity Drug Strategy Takes Aim at 67% Treatment Dropout Rate - StockTitan
Palatin spikes as FDA clears mid-stage trial for weight loss therapy - MSN
Palatin starts Phase 2 obesity study of bremelanotide with Zepbound - MSN
HB Wealth Management LLC Has $127,000 Stock Position in Palatin Technologies, Inc. (NYSEAMERICAN:PTN) - Defense World
Palatin Technologies (NYSEAMERICAN:PTN) Shares Cross Above 200-Day Moving Average – What’s Next? - Defense World
Palatin Technologies Inc (AMEX: PTN) Analysts Expect It Could Climb 93.76% From Current Levels. - Stocks Register
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivota - GuruFocus.com
Palatin reports positive Phase 2b results in diabetic nephropathy - Yahoo Finance
First Patient Dosed in Phase 2 Clinical Study of Palatin's Breme - GuruFocus.com
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy - PR Newswire
Palatin Technologies announces warrant exercise for ~$3.4M gross proceeds - MSN
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds - The Eastern Progress Online
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results - The Eastern Progress Online
Palatin Technologies (BUE:PTN) Financial Strength : 4 (As of Sep. 2024) - GuruFocus.com
Thinking about buying stock in MedAvail Holdings, Trio-Tech Inte - GuruFocus.com
PTN (Palatin Technologies) Price-to-Free-Cash-Flow : N/A (As of Dec. 01, 2024) - GuruFocus.com
PTN (Palatin Technologies) COGS-to-Revenue : 0.00 (As of Sep. 2024) - GuruFocus.com
Palatin Technologies stock stays Buy rated after completing Phase 2 enrollment in UC trial - Investing.com UK
Palatin Announces Completion of Patient Enrollment in Phase 2 St - GuruFocus.com
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis – Company AnnouncementFT.com - Financial Times
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis - PR Newswire
Palatin Technologies (FRA:PTN) Retained Earnings : €-405.08 Mil (As of Sep. 2024) - GuruFocus.com
Palatin Technologies (FRA:PTN) Graham Number : €N/A (As of Sep. 2024) - GuruFocus.com
Palatin Technologies (FRA:PTN) Float Percentage Of Total Sh - GuruFocus.com
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleco - GuruFocus.com
Palatin Technologies, Inc. (AMEX:PTN) Q1 2025 Earnings Call Transcript - Insider Monkey
Palatin Technologies Inc (PTN) Quarterly 10-Q Report - Quartzy
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Challenges - GuruFocus.com
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ... - Yahoo Finance
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ... By GuruFocus - Investing.com Canada
Palatin Technologies Inc. (PTN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Palatin Technologies Inc. 주식 (PTN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DEVEER ROBERT K JR | Director |
Apr 11 '24 |
Buy |
2.12 |
6,000 |
12,703 |
40,845 |
| DEVEER ROBERT K JR | Director |
Mar 06 '24 |
Sale |
2.00 |
11,700 |
23,434 |
34,845 |
1.03%
자본화:
|
볼륨(24시간):